1 / 19

CP 3 R Reports for Population Based Studies

CP 3 R Reports for Population Based Studies. Presented at the NAACCR Annual Conference Quebec City June 22, 2010. What are CP 3 R Reports?. Cancer Program Practice Profile Reports Developed by the Commission on Cancer

irish
Download Presentation

CP 3 R Reports for Population Based Studies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CP3R Reports for Population Based Studies Presented at the NAACCR Annual Conference Quebec City June 22, 2010

  2. What are CP3R Reports? • Cancer Program Practice Profile Reports • Developed by the Commission on Cancer • Web based comparative reports for COC approved facilities to assess local adherence to standards of care • Designed to implement concepts of best practices that will diminish disparities in cancer care across COC approved programs

  3. 6 currently defined measures • Breast cancer – Radiation therapy is administered within 1 year to women < age 70 who receive BCC • Breast cancer – Combination chemo is received within 4 mos. by women who are • < age 70 • T1cN0M0 or Stage II or Stage III • Hormone receptor negative

  4. 6 currently defined measures • Breast cancer – Hormone therapy is received within 1 year by women who are • T1cN0M0 or Stage II or Stage III • Hormone receptor positive • Colon cancer – At least 12 regional lymph nodes are removed & examined for resected colon cancers

  5. 6 currently defined measures • Colon cancer – Adjuvant chemo is received within 4 mos. by patients who are • < age 80 • Stage III (lymph node positive) • Have surgical resection • Rectal cancer – Radiation therapyis administered within 6 mos. to patients • < age 80 • T4N0M0 or Stage III • Have surgical resection

  6. Hospital Registry Query • Report requested by KY hospitals • To identify all eligible patients for each CP3R measure and • To calculate percentage of concordant vs. non-concordant cases for the hospital

  7. Sample query: Stg III Colon • Age between 18-79 • Seq. number = 00 or 01 • Site code = C18.0 or C18.2-C18.9 • Behavior code = 3 • Diagnosis date between 1/1/2007 and 12/31/2007 • Histology = epithelial tumors (8000, 8001, …) (List provided by COC)

  8. Sample query (continued) • pTNM Stage Group = III, IIIA, IIIB, or IIIC • Surgery at the Primary Site = 30-90 • Regional Nodes Positive = 1-90, 95, or 97 • Patient alive for at least 120 days after surgery

  9. Sample hospital report

  10. Central Registry application • Can assess concordance in KY with national standards of care • Can determine ‘concordant’ vs. ‘non- concordant’ groups and then examine differences in age, race, area of residence, etc. in a population

  11. Central Registry Query • Modifications needed for CCR query • Delete class of case condition • Add ‘State at Diagnosis’ = KY • Use Stage Group criteria based on derived Collaborative Stage instead of AJCC Stage variables

  12. Example: 2007 Stage III Colon Cancer Cases • Initial query: 243 eligible cases • Compared Derived Stage Group to pTNM Stage Group • 3 cases were pTNM Stage IV (metastatic); thus deleted • Final KY 2007 Stage III Colon cases (eligible per CP3R criteria) was 240.

  13. Initial Assessment • No chemotherapy • None given 31 • Recommended, unk. if given 14 • Unknown if rec. or given 25 • Total ‘non-concordant’ 70 29.2% • Chemotherapy considered or given • Chemo given 161 • Chemo contraindicated 1 • Chemo refused 8 • Total ‘concordant’ 170 70.8%

  14. Follow Back • Text documentation was reviewed on all cases where chemo was refused; all were verified. • All cases where chemo was not reported to the CCR were followed back, using • Calls to hospital registrars • Calls, letters, & electronic access to physician offices • Calls, letters, & electronic access to OP facilities • On site visits • Calls and letters to out of state CCR contacts, registrars and physicians

  15. Final results

  16. Chemo Time Frame Issues • 9 cases where chemo was found to be given, no date for chemo could be found • 7 cases had chemotherapy received more than 120 days beyond diagnosis date • Of these, 4 patients had various co-morbidities that delayed their chemotherapy start date, even though it had been recommended within the time frame. • 2 cases that had chemotherapy more than 250 days after diagnosis were reviewed and recoded; the chemo was determined to be subsequent treatment.

  17. Concordant vs. Non-concordant

  18. Other Findings • More information on chemotherapy given, refused, or contraindicated was found on 62 patients • 33 were reported to KCR by COC hospitals • 29 were reported by non-COC facilities • It took approximately 70 hours to follow back on 70 cases.

  19. Summary In 2007, of Kentuckians with Stage III colon cancer • 85% received chemotherapy (9 cases (3.7%) had an unknown chemo start date; 7 cases (2.9%) had a chemo start date beyond 120 days ) • 9% refused chemotherapy • 3% had medical contraindications • 3% have no documentation about chemotherapy Analysis of characteristics of ‘concordant’ vs. ‘non-concordant’ groups yielded no significant results.

More Related